Terms: = Leukemia AND MSH6, GTBP, P52701, 2956, ENSG00000116062, HSAP, HNPCC5 AND Treatment
16 results:
1. Constitutional Mismatch Repair Deficiency Syndrome as a Cause of Numerous Malignancies in a Teenage Patient-A Case Report.
Samborska M; Galli D; Achkar R; Thambyrajah S; Derwich K
J Pediatr Hematol Oncol; 2023 Oct; 45(7):e917-e920. PubMed ID: 37526375
[TBL] [Abstract] [Full Text] [Related]
2. The Challenge of Diagnosing Constitutional Mismatch Repair Deficiency Syndrome in Brain Malignancies from Young Individuals.
Carrato C; Sanz C; Muñoz-Mármol AM; Blanco I; Pineda M; Del Valle J; Dámaso E; Esteller M; Musulen E
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33924881
[TBL] [Abstract] [Full Text] [Related]
3. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia.
Li B; Brady SW; Ma X; Shen S; Zhang Y; Li Y; Szlachta K; Dong L; Liu Y; Yang F; Wang N; Flasch DA; Myers MA; Mulder HL; Ding L; Liu Y; Tian L; Hagiwara K; Xu K; Zhou X; Sioson E; Wang T; Yang L; Zhao J; Zhang H; Shao Y; Sun H; Sun L; Cai J; Sun HY; Lin TN; Du L; Li H; Rusch M; Edmonson MN; Easton J; Zhu X; Zhang J; Cheng C; Raphael BJ; Tang J; Downing JR; Alexandrov LB; Zhou BS; Pui CH; Yang JJ; Zhang J
Blood; 2020 Jan; 135(1):41-55. PubMed ID: 31697823
[TBL] [Abstract] [Full Text] [Related]
4. Cancer prevention by aspirin in children with Constitutional Mismatch Repair Deficiency (CMMRD).
Leenders EKSM; Westdorp H; Brüggemann RJ; Loeffen J; Kratz C; Burn J; Hoogerbrugge N; Jongmans MCJ
Eur J Hum Genet; 2018 Oct; 26(10):1417-1423. PubMed ID: 29904176
[TBL] [Abstract] [Full Text] [Related]
5. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid leukemia Study Group.
Rea D; Ame S; Berger M; Cayuela JM; Charbonnier A; Coiteux V; Cony-Makhoul P; Dubruille V; Dulucq S; Etienne G; Legros L; Nicolini F; Roche-Lestienne C; Escoffre-Barbe M; Gardembas M; Guerci-Bresler A; Johnson-Ansah H; Rigal-Huguet F; Rousselot P; Mahon FX;
Cancer; 2018 Jul; 124(14):2956-2963. PubMed ID: 29723417
[TBL] [Abstract] [Full Text] [Related]
6. msh6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia.
Evensen NA; Madhusoodhan PP; Meyer J; Saliba J; Chowdhury A; Araten DJ; Nersting J; Bhatla T; Vincent TL; Teachey D; Hunger SP; Yang J; Schmiegelow K; Carroll WL
Haematologica; 2018 May; 103(5):830-839. PubMed ID: 29449434
[TBL] [Abstract] [Full Text] [Related]
7. Protective effect of human serum amyloid P on CCl4-induced acute liver injury in mice.
Cong M; Zhao W; Liu T; Wang P; Fan X; Zhai Q; Bao X; Zhang D; You H; Kisseleva T; Brenner DA; Jia J; Zhuang H
Int J Mol Med; 2017 Aug; 40(2):454-464. PubMed ID: 28627620
[TBL] [Abstract] [Full Text] [Related]
8. Identification of a genetically defined ultra-high-risk group in relapsed pediatric T-lymphoblastic leukemia.
Richter-Pechańska P; Kunz JB; Hof J; Zimmermann M; Rausch T; Bandapalli OR; Orlova E; Scapinello G; Sagi JC; Stanulla M; Schrappe M; Cario G; Kirschner-Schwabe R; Eckert C; Benes V; Korbel JO; Muckenthaler MU; Kulozik AE
Blood Cancer J; 2017 Feb; 7(2):e523. PubMed ID: 28157215
[TBL] [Abstract] [Full Text] [Related]
9. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia.
Mar BG; Bullinger LB; McLean KM; Grauman PV; Harris MH; Stevenson K; Neuberg DS; Sinha AU; Sallan SE; Silverman LB; Kung AL; Lo Nigro L; Ebert BL; Armstrong SA
Nat Commun; 2014 Mar; 5():3469. PubMed ID: 24662245
[TBL] [Abstract] [Full Text] [Related]
10. High-grade brain tumors in siblings with biallelic msh6 mutations.
Ilencikova D; Sejnova D; Jindrova J; Babal P
Pediatr Blood Cancer; 2011 Dec; 57(6):1067-70. PubMed ID: 21674763
[TBL] [Abstract] [Full Text] [Related]
11. A new, lineage specific, autoup-regulation mechanism for human glucocorticoid receptor gene expression in 697 pre-B-acute lymphoblastic leukemia cells.
Geng CD; Vedeckis WV
Mol Endocrinol; 2011 Jan; 25(1):44-57. PubMed ID: 21084380
[TBL] [Abstract] [Full Text] [Related]
12. Compound heterozygosity for msh6 mutations in a pediatric lymphoma patient.
Peters A; Born H; Ettinger R; Levonian P; Jedele KB
J Pediatr Hematol Oncol; 2009 Feb; 31(2):113-5. PubMed ID: 19194194
[TBL] [Abstract] [Full Text] [Related]
13. A conserved molecular mechanism is responsible for the auto-up-regulation of glucocorticoid receptor gene promoters.
Geng CD; Schwartz JR; Vedeckis WV
Mol Endocrinol; 2008 Dec; 22(12):2624-42. PubMed ID: 18945813
[TBL] [Abstract] [Full Text] [Related]
14. [A study to determine the safety and efficacy of imatinib mesylate in patients with chronic phase of chronic myeloid leukemia after interferon therapy failure. Four year follow-up].
Hołowiecki J; Konopka L; Bober G; Giebel S; Ceglarek B; Kos K; Stella-Hołowiecka B; Kruzel T; Kopera M; Bartkowska-Chrobok A; Pszenna E; Sikorska A; Pieńikowska-Grela B
Pol Arch Med Wewn; 2006 Jun; 115(6):535-44. PubMed ID: 17263225
[TBL] [Abstract] [Full Text] [Related]
15. Assessment of mismatch repair function in leukaemic cell lines and blasts from children with acute lymphoblastic leukaemia.
Matheson EC; Hall AG
Carcinogenesis; 2003 Jan; 24(1):31-8. PubMed ID: 12538346
[TBL] [Abstract] [Full Text] [Related]
16. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia.
Cannistra SA; DiCarlo J; Groshek P; Kanakura Y; Berg D; Mayer RJ; Griffin JD
Leukemia; 1991 Mar; 5(3):230-8. PubMed ID: 1826536
[TBL] [Abstract] [Full Text] [Related]
